Missing Data in Randomized Clinical Trials for Weight Loss: Scope of the Problem, State of the Field, and Performance of Statistical Methods by Elobeid, Mai A. et al.
Missing Data in Randomized Clinical Trials for Weight
Loss: Scope of the Problem, State of the Field, and
Performance of Statistical Methods
Mai A. Elobeid
1,4, Miguel A. Padilla
1, Theresa McVie
2, Olivia Thomas
3, David W. Brock
4, Bret Musser
5,
Kaifeng Lu
5, Christopher S. Coffey
1, Renee A. Desmond
6, Marie-Pierre St-Onge
7, Kishore M. Gadde
8,9,
Steven B. Heymsfield
5, David B. Allison
1,10,11*
1Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 2BlueCross BlueShield of
Tennessee, Chattanooga, Tennessee, United States of America, 3Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham,
Alabama,United States of America, 4Division ofCardiovascularDisease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama,UnitedStates of
America,5Merck & Co., Inc, Rahway, New Jersey, UnitedStates ofAmerica,6DivisionofBiostatisticsand Bioinformatics, Comprehensive CancerCenter, UniversityofAlabama at
Birmingham, Birmingham, Alabama, United States of America, 7New York Obesity Research Center, St. Luke’s/Roosevelt Hospital & College of Physicians & Surgeons, New York,
New York, United States of America, 8Departments of Psychiatry, Duke University Medical Centre, Durham, North Carolina, United States of America, 9The Research Triangle
Research Institute, Research Triangle Park, North Carolina, United States of America, 10Clinical Nutrition Research Center, University of Alabama at Birmingham, Birmingham,
Alabama, United States of America, 11Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
Abstract
Background: Dropouts and missing data are nearly-ubiquitous in obesity randomized controlled trails, threatening validity
and generalizability of conclusions. Herein, we meta-analytically evaluate the extent of missing data, the frequency with which
various analytic methods are employed to accommodate dropouts, and the performance of multiple statistical methods.
Methodology/Principal Findings: We searched PubMed and Cochrane databases (2000–2006) for articles published in
English and manually searched bibliographic references. Articles of pharmaceutical randomized controlled trials with weight
loss or weight gain prevention as major endpoints were included. Two authors independently reviewed each publication for
inclusion. 121 articles met the inclusion criteria. Two authors independently extracted treatment, sample size, drop-out
rates, study duration, and statistical method used to handle missing data from all articles and resolved disagreements by
consensus. In the meta-analysis, drop-out rates were substantial with the survival (non-dropout) rates being approximated
by an exponential decay curve (e
2lt) where l was estimated to be .0088 (95% bootstrap confidence interval: .0076 to .0100)
and t represents time in weeks. The estimated drop-out rate at 1 year was 37%. Most studies used last observation carried
forward as the primary analytic method to handle missing data. We also obtained 12 raw obesity randomized controlled trial
datasets for empirical analyses. Analyses of raw randomized controlled trial data suggested that both mixed models and
multiple imputation performed well, but that multiple imputation may be more robust when missing data are extensive.
Conclusion/Significance: Our analysis offers an equation for predictions of dropout rates useful for future study planning.
Our raw data analyses suggests that multiple imputation is better than other methods for handling missing data in obesity
randomized controlled trials, followed closely by mixed models. We suggest these methods supplant last observation
carried forward as the primary method of analysis.
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Introduction
‘‘Well conducted clinical trials are the fastest and safest way to
find improved treatments and preventions…’’ NIDDK [1].
Obesity is associated with and believed to cause adverse
conditions such as cardiovascular disease, stroke, type 2 diabetes
mellitus, certain forms of cancer [2], and decreased longevity [3].
It is estimated that over 50 million Americans are obese, and
recent data show no decreases in prevalence [4]. Currently
available treatments are only of moderate efficacy, and not all
treatments work for all individuals. Thus, it is critical to identify
and evaluate new alternative treatments for both efficacy and
safety. Several important questions about how to best design,
interpret, and analyze randomized controlled trials (RCTs) for
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6624obesity treatments remain unanswered (for video proceedings of
an NIH-funded conferenceonthistopic,see:http://main.uab.edu/
Shrp/Default.aspx?pid=97738#schedule).
One of the most challenging aspects of obesity RCTs is the
seemingly inevitable high rate of loss to follow-up (‘dropout’). A
recent editorial from NIH scientists began by praising one of the
largest, best-evaluated pharmaceutical obesity RCTs conducted
but concluded its opening with the remark that ‘‘an overriding
concern is the failure to obtain final weight measurements on
about half of the randomized participants.’’ Such high losses to
follow-up are not atypical and create several problems, including:
(A) reduced statistical power; (B) potential loss of internal validity if
data are not missing completely at random (MCAR); and (C)
challenges in analyzing the resulting incomplete datasets.
It is difficult to evaluate the scope of this problem and the
appropriateness of investigators’ responses to it because there
has been no formal quantitative integration of the published
information on dropout rates (DORs) and which methods are
most commonly used to accommodate missing data in obesity
RCTs. Hence, meta-analysis was employed to extract and model
DOR, while real raw data sets were used to evaluate the
performance of statistical strategies for handling missing data.
Although simulation s t u d i e sa n dd e r i v a t i o n so fa s y m p t o t i c
properties of some available statistical methods for accommo-
dating missing data in inferential testing are available, there is no
guarantee that the conditions simulated or under which the
asymptotic properties were derived effectively represent real
data in terms of factors such as the presence of outliers, degrees
of dropout, shape of marginal distributions (e.g., extent of non-
normality), or covariance structure among observations. There-
fore, the purpose of this project was to conduct two separate
evaluations to estimate the scope of the problem. First, we
conducted a meta-analysis of obesity RCTs. Second, we
analyzed multiple real raw datasets through various missing
data methodologies. The results of such analyses have implica-
tions for the design of future obesity RCTs, for the interpretation
of the relative rigor of individual past and future obesity RCTs,
and importantly, for the choice of statistical method for their
analysis.
Methods
Quantitative synthesis of published research: DORs and
methods used to accommodate them
Data Source. Published articles were retrieved using searches
performed on: 1) electronic databases (MEDLINE and Cochrane
database publications), 2)Cross-referencefrom original publications
and review articles, and 3) manual searching of bibliographic
references. We searched PubMed to identify publications for
inclusion, imposing the following limits: date, RCTs, human
studies, English language and peer-reviewed.
Inclusion Criteria. All studies used had to meet the
following inclusion criteria: 1) the data were from human
studies, 2) the study was an RCT, 3) the study reported DORs,
4) the study used one or more pharmaceuticals vs placebo, 5)
weight loss and/or weight gain prevention was a study outcome, 6)
the study was published in a peer-reviewed journal, 7) the study
was published in the English language, and 8) the study was
published between January 1, 2000 and December 31, 2006. One
study (44) published in print in 2007 was included in our analysis
because it showed up in our search in 2006 as an epub.
Multiple publication biases (including the same subjects
reported in two or more papers) were avoided by carefully
examining each study for duplication. All articles were double-
checked independently for inclusion criteria by two of the authors
(M.E. and O.T). Discrepancies were resolved by consensus. D. W.
B. conducted final inclusion criteria verification (10%) on a
random sample of the identified articles and obtained 100%
agreement. One of three other authors (D.B.A, C.S.C., R.A.D)
checked the coded information obtained from each article and
again, discrepancies were resolved by consensus.
Study Searching. We divided our keyword search into four
categories: 1) ‘obesity’ OR ‘weight loss’ OR ‘weight gain
prevention’, which yielded 2111 studies, 2) sibutramine OR
orlistat OR topiramate OR rimonabant OR recombinant leptin,
which yield 286 studies, 3) combined categories 1 AND 2 of
weight-related outcomes and pharmaceuticals, which yielded 199
studies, and 4) combined category 3 AND ‘placebo’, which yielded
141 studies. The 141 studies were further screened for inclusion
and resulted in a final sample of 89 studies from our PubMed
search. Secondly, we searched the Cochrane databases for meta-
analyses of weight loss interventions using ‘weight loss’ and
‘obesity’ as keywords, which yielded 41 reviews of which 3 were
reviews of pharmaceutical trials with weight loss or weight gain
prevention as a major endpoint. Bibliographies of the Cochrane-
derived studies were searched for publications eligible for
inclusion. The search of all bibliographies yielded 32 additional
studies for inclusion. Although this search was not expected to
retrieve pharmaceutical obesity RCTs, it provided a sufficiently
large sample to yield reasonably precise estimates of DORs as a
function of study duration, which was our goal.
Data Extraction of study-level variables and
results. Two reviewers (M.E. and O.T.) extracted the following
data from all articles collected and resolved disagreements by
consensus (21, 26–145; Appendix S1). The variables of interest
included:
1) general information (authors and year of publication), 2)
duration of the trial, 3) total sample size defined as the number of
subjects randomized, 4) DORs defined as the total number of
subjects that dropped out from the trial from the time of
randomization to the time of completion, 5) methods used to
accommodate missing data; e.g. completer’s only, last observation
carried forward (LOCF), mixed model (MM), and multiple
imputation (MI), and 6) the specific drugs used for treatment.
Modeling DORs. In the meta-analyses for the i
th published
article, the proportion of subjects remaining in the corresponding
study and on whom a final endpoint measurement was obtained at
time t, was recorded and denoted as ^ p pi,t. We then fit an exponential
decay curve to these proportions using SPSS’ non-linear regression
and the model: ^ p pi,t~e{lt, a simple model with a constant rate of
drop-out over time. We solved for the value of l by minimizing the
sum of squared model residuals. Models were run both unweighted
and weighted by the inverse of the variance for each observation.
Standard errors, confidence intervals and p-values were obtained by
bootstrapping with 1,000 bootstrap samples.
Analysis of Multiple Real Raw Datasets to Evaluate
Method Performance
Acquisition of RCT Raw Datasets. We obtained 12 real
raw datasets from obesity RCTs conducted by (M.P.S., K.M.G.,
S.B.H., and D.B.A.) and one data set from the NIDDK data
archive. All datasets were from an intervention for weight loss or
weight gain prevention (Table 1).
Generation of Plasmode Datasets. A plasmode is a
‘‘numerical scientific example, preferably derived from data in a
physical model, in which the relations generating measures are
controlled and known to fit an explicit theoretical model’’ [5]. It is
generally a ‘real’ data set in the sense that it is not a function of a
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such a way that some aspect of the truth is known. Plasmodes
constructed from real datasets have the advantage of real data in
that they can be, by definition, realistic in terms of marginal
distributions, covariance structures, presence of outliers, and
patterns of dropout. Yet at the same time, they retain a key
advantage of traditional simulations. Specifically, manipulation
can be done so that some aspects of the data generating process
are known with certainty. This allows one to empirically evaluate
performance characteristics of analytic methods by determining
the frequency with which a method obtains the known right
answers.
We generated plasmodes under both the null and alternative
hypotheses from the obtained 12 raw datasets. To generate
plasmodes under the null hypothesis of no treatment effect on
weight for each of the 12 datasets, we randomly permuted the
treatment assignment indicators. This perfectly preserved the real
data’s marginal distributions, covariance structures, presence of
outliers, and patterns of dropout, yet assured that all null
hypotheses of no effect of treatment were true. However, it does
not preserve any relation between missingness and treatment
assignment. By analyzing such permuted datasets and observing
the frequency that statistically significant results were obtained, we
were able to evaluate whether our procedures were properly
holding the type I error rate to the set level.
To generate plasmodes under the alternative hypothesis of some
treatment effect on weight, constants were added to the body
weights of each treatment group in each of the above randomly
permuted plasmodes. The added constants were meant to mimic
the treatment trajectory in Wadden et al. [6], which are
trajectories common in obesity research. This essentially simulates
data for power evaluation by imposing a treatment effect on the
permuted datasets. The treatment effect was generated to have
50% power for the datasets in the LOCF condition. Power of 50%
was chosen because at such middling levels it is relatively easy to
see differences among methods in power that would not be easily
apparent at very high power levels such as 90%. The LOCF
condition was chosen for two reasons. First, it is in a sense a
‘‘complete dataset’’, so when a dataset is analyzed with the missing
values added back, one can see how much power has been lost.
Second, generating a 50% power under the completer’s only
condition caused the power when analyzing the data under the
LOCF condition to be as high as 100% in some dataset.
Statistical Analysis of Real & Plasmode RCT
Datasets. Four different strategies for analyzing data with
missing values were used to analyze the 12 real datasets and
generated plasmodes. Plasmode simulations and all analyses of real
and plasmode datasets were performed on SAS 9.1. With the
exception of the intent-to-treat last observation carried forward
(ITT-LOCF) method (defined below), patients in all of these
methods had a baseline measurement and at least one post
baseline measurement. Additionally, weight loss is calculated as
the difference between weight at the end minus weight at the
beginning of the trial. It should be noted that multiple imputation
(MI), mixed model (MM), and completers only analysis (but not
necessarily LOCF) will provide consistent parameter estimates (a
consistent estimator is one that converges in probability to its
estimate asymptotically in the sample size) if the missing values are
MCAR. However, only MI and maximum likelihood (ML) will
provide consistent parameter estimates when the missing values
are missing at random (MAR), a less restrictive and more realistic
situation (for further reading see Gadbury et. al. [7]).
Completers Only. In the completers only analysis, we used
only the data for patients who came in for the baseline visit and the
last follow up visit; that is, any patients who were missing any visits
in the middle were still included.
Last Observation Carried Forward. In the LOCF analysis,
if a subject’s weight was missing at a visit, then the weight from the
most proximal prior visit was used. For example, if a study has 5
visits and the participant only missed visit 3, then the value from
visit 2 would be used as the participant’s weight for visit 3. LOCF
was conducted under two methods.
Intent- To- Treat Last Observation Carried
Forward. This method preserved the most data in that it
allowed for the possibility of carrying the baseline measurement
forward to the end of the trial if a subject dropped out immediately
Table 1. Real Datasets Acquired.
Study
Number Reference
Number
Randomized
Number of
completers
Duration
(weeks) Treatment
Number of post-baseline
measurement points
1 RCT 1[17] 186 154 12 Herbal Supplement
contain Ephedrine
6
2 RCT 2 [18] 102 87 12 Herbal Supplement
contain Ephedrine
7
3 RCT 3 [19] 96 68 12 Acupressure device
for weight loss
7
4 RCT 4 [20] 60 51 32 Zonisamide 6
5 RCT 5 [21] 30 21 12 Atomoxetine 5
6 RCT 6 [22] 75 47 12 Meal Replacement (Soy) 6
7 RCT 7 [23] 135 84 12 Herbal Supplement Contain
Garcinia Cambogia
7
8 RCT 8 [24] 100 30 40 Meal Replacement (Soy) 3
9 RCT 9 [25] 100 58 12 Meal Replacement (Soy) 11
10 DPP [6] 2103 242 48 months Metformin 9
11 NPY-1 [26] 206 159 12 Neuropeptide Y5R 5
12 NPY-1 [26] 1661 854 52 Neuropeptide Y5R 11
Abbreviations: RCT, randomized controlled trial; DPP, Diabetes Prevention Program; NPY-1, neuropeptide-Y-1.
doi:10.1371/journal.pone.0006624.t001
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Therefore, it is possible to have some cases with only baseline
measurements.
Last Observation Carried Forward. In this LOCF
method, patients with only baseline measurements were not
used. That is, all patients have a baseline and at least one post-
baseline measurement of weight.
Multiple Imputation. MI is a missing data technique that
imputes plausible values for the missing values. One generates m
datasets with plausible values imputed for the missing values. Each
of the m datasets is separately analyzed using the desired model (i.e.
regression, ANOVA, etc.), generating m sets of parameter estimates.
Themsetsofparameterestimatesarethencombinedusingstandard
rules for MI analyses [8,9]. The combined parameter estimates are
then used for hypothesis testing and inference. For this study, the
degrees of freedom for the combined parameter estimates were
adjusted as outlined by Barnard and Rubin [10]. Additionally, only
group membership (i.e., treatment or placebo) and measurements
over time were used in the imputation process. Imputations were
conducted using two methods.
MI for Monotone Missing Value. This imputation was
conducted by first imputing enough data to impose a monotone
missing data pattern on the original data via a Markov Chain
Monte Carlo (MCMC) algorithm. A dataset with variables X1, X2,
…, Xp has a monotone missing data pattern when Xi is missing
and subsequently Xj for j.I is missing for a patient. If the missing
data pattern was already monotone, then this step was skipped.
Monotone missing data occurs frequently in longitudinal studies.
The data were then imputed by assuming a monotone missing
data pattern using the regression method proposed by Rubin [11].
MI for General Missing Data Pattern. In this imputation
scheme, no assumption was made about the pattern of missing
values except that they are MAR. The data were imputed via an
MCMCalgorithmwith multiplechainsand 1200burn-initerations.
The MCMC algorithm used here is a two-step iterative process that
begins by imputing plausible values for the missing values given the
observed values in order to generate a complete data set [9].
Second, the complete data set is then used to compute the
parameters of the posterior distribution. These parameters are then
fed back into the first step to imputing plausible values for the
missing values, which are then used in the next posterior step, etc.
The process iterates long enough to reach the stationary or desired
distribution, which in this case is multivariate normal.
Mixed Model. In this strategy, when a dataset has missing
values all available data are used to directly estimate model
parameters via ML. More specifically, restricted maximum
likelihood (REML) was used in these applications. No participant
is dropped from the analysis because all available data are used to
obtain parameter estimates. The REML methods were conducted
with a mixed model treating time as continuous or categorical and
modeling V, the variance of y, in two ways (for further details see
[12]). When time was treated as continuous, V was modeled as a
function of the covariances of the random effects and random
errors. In this particular case, the covariance of the random effects
was unstructured, and the random errors were assumed
independent and constant (homogenous). When time was treated
as categorical, V was modeled as a function of the unstructured
covariance of the random errors. The one exception was RCT 9.
Large amount of missing data in RCT 9 led to unstable estimates
with use of an unstructured covariance matrix, so unstructured
covariances were replaced with autoregressive lag 1 [AR(1)]
covariances when treating time as continuous or categorical.
Results
Scope of Missing Data Due to Dropouts
Our search identified 121 articles meeting inclusion criteria. The
unweighted mean DORs of the 121 studies was 26.3%. DORs
variedsubstantiallyamongstudiesand,notsurprisingly,asafunction
of study duration. The exponential function fitted to the meta-
analysis data was statistically significant. In the unweighted analysis,
the exponential coefficient (i.e., ‘hazard’) was .0088 (asymptotic p-
value=3.2*10
228; 95% bootstrap CI: .0076 to .0100) and in the
weighted analysis was .0069. The data and the fitted curves are
shown in Figure 1. As can be seen, at 1-year, we would expect 37%
(SE<1.76%)ofpatients tohavedropped out.Thiscurve can be used
Figure 1. Scatter plot of dropouts over time with fitted exponential decay curve. Drop-out rates for six small (N=18 to 60) studies that
reported zero drop-outs were set to 1% to allow the analyses to proceed.
doi:10.1371/journal.pone.0006624.g001
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ceutical studies. In doing so, it should be noted that the unweighted
and weighted predictions are quite similar and appear to fit the data
in an unbiased fashion through approximately 75 weeks. After that,
these predictions diverge and appear a bit biased.Hence, their use in
trials extending beyond 75 weeks is questionable, and more evidence
from very long trials is needed.
Type of methods to adjust for attrition bias. Figure 2
displays the methods used to accommodate missing data in the
published RCTs. As can be seen, it has now become the norm to
do some type of intent-to-treat (ITT) analysis, though roughly 14%
of studies still use only a completers analysis. The vast majority of
studies that do ITT analyses use nothing more sophisticated that
some variant of LOCF, and those few that do almost universally
used some variation of a mixed model.
Performance of Methods. Table 2 displays the amount of
observed and missing data points in each of the 12 real dataset.
Table 3 displays mean differences (MD), and p-values for the
actual analysis, type-1 error rates under the permutation-
constructed nulls, and power for the ITT-LOCF, LOCF and
completers only. Table 4 and 5 display the results for the MI
methods. Lastly, Table 5 and 6 show the results of the Mixed
Model methods treating time as continuous and categorical,
respectively.
Performance with Actual Data. Two components were
assessed with respect to the actual data. First, we examined
whether the overall conclusions are affected by the choice of
analysis method. Second, we examined how robust the conclusions
were by comparing the p-values obtained for the standard t-test
and the permutation test.
In general, regardless of the analysis method chosen, the overall
conclusion of whether or not a significant effect was observed did
not change if a result was deemed to be significant (i.e. the p-value
was below the standard 5% level). The one exception was RCT 10
in which both completers only and Mixed II Cat (defined in
Table 6) obtained non-significant results, whereas all other
methods obtained significant results. This illustrates, among other
things that the conventional wisdom that completers only analyses
are liberal and that LOCF is conservative does not necessarily hold
in all datasets.
As can be seen in Table 3, all of the permuted p-values were close
toobservedp-values,withtheexceptionofRCT8undercompleters
only in which the permutation test gave a slightly higher p-value.
This suggests that the datasets considered in this work were very
robust to the underlying assumptions of the t-test for these three
approaches. The results in Table 4 suggest that the MI methods
Figure 2. Percent of published studies using methods to
accommodate drop-outs. For this chart, when an article reported
using more than one analytic procedure, it was coded as having used
the ‘best’ of the procedures it employed where the ranking was in
ascending order: Completers only, LOCF (any variation on last
observation carried forward); an unspecified intent to treat (ITT)
analysis; any of several mixed model analyses (mixed), or multiple
imputation (MI). ‘Completers’ denotes completer only analysis, ITT-NOS,
ITT not otherwise specified, ‘No Drop Outs’, no dropouts reported, and
NS, not specified.
doi:10.1371/journal.pone.0006624.g002
Table 2. Percent of Observed and Missing Data Points from the 12 Obesity RCT Datasets.
Intent-to-Treat Baseline-Post-baseline Imposed Treatment Mean
Data Set
Total Data
Points
Observed
Data Points
Proportion
Missing
Total Data
Points
Observed
Data Points
Proportion
Missing
Last Time
Point
RCT 1 1116 1029 .08 1116 1029 .08 1.90
RCT 2 714 672 .06 714 672 .06 2.18
RCT 3 658 538 .18 644 536 .17 1.33
RCT 4 360 334 .07 348 332 .05 2.35
RCT 5 150 126 .16 130 122 .06 6.10
RCT 6 450 330 .27 354 314 .11 1.65
RCT 7 945 716 .24 833 700 .16 2.75
RCT 8 300 239 .20 249 222 .11 2.65
RCT 9 1089 586 .46 913 570 .38 2.30
RCT 10 18927 13133 .31 18639 13101 .30 0.64
RCT 11 1030 922 .10 1030 922 .10 0.23
RCT 12 18271 13344 .27 17105 13238 .23 0.66
Abbreviations: RCT, randomized controlled trial.
doi:10.1371/journal.pone.0006624.t002
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observed between the permuted and observed p-values. The biggest
differenceswere observedwithRCT9,whichhadalarge amountof
missing data. For the plasmode datasets derived from RCT 9, the
observed p-values are noticeably smaller than the permuted p-
values. However, the noticeably smaller observed p-values were still
nowherenear significantandmore importantly evenforRCT9,the
empirical type-1 error rates when MI is used at the .05 alpha level
were well preserved (see below). In contrast, for mixed models,
Table 5 and 6 reveals that this same concern exists with RCT 9.
However,inthecaseofmixedmodelswithRCT9andRCT10,the
empirical type-1 error rates at the .05 alpha levels were not well
preserved(seebelow). Hence, these results suggest that mixed model
approaches should be viewed with skepticism in conditions similar
to those prevailing in RCT 9 and RCT 10 which includes modest
sample size (for RCT 9), a large proportion of missing data (for both
RCT 9 and RCT 10), and a high ratio of measurement time-points
to completing patients.
Table 3. Analysis of ITT-LOCF, LOCF, and completers for handling missing data in the 12 raw datasets using ordinary least squares.
Actual Analysis Null Imposed Treatment Effect
ITT-LOCF Observed Mean Difference Observed p-value Permuted p-value Empirical a Mean Difference Power
RCT 1
a 4.07 1610
25 ,10
25 .0479 1.99 .539
RCT 2
a 2.60 .0103 .0113 .0522 2.13 .528
RCT 3 0.62 .2827 .2837 .0510 1.19 .515
RCT 4 5.01 ,10
25 ,10
25 .0505 2.26 .489
RCT 5 7.17 .0022 .0005 .0469 5.29 .482
RCT 6 0.03 .9551 .9561 .0510 1.17 .414
RCT 7 1.66 .2344 .2252 .0478 2.55 .429
RCT 8 1.66 .4133 .4270 .0485 3.71 .413
RCT 9 0.71 .3881 .3971 .0517 1.57 .443
RCT10 1.90 ,10
25 ,10
25 .0474 0.56 .537
RCT 11
a 1.30 .0009 .0006 .0531 0.82 .541
RCT 12 1.05 .0001 .0003 .0496 0.53 .481
LOCF
RCT 1
a 4.07 1610
25 ,10
25 .0479 1.99 .539
RCT 2
a 2.60 .0103 .0113 .0522 2.13 .528
RCT 3 0.61 .2964 .2976 .0509 1.21 .515
RCT 4 4.95 ,10
25 ,10
25 .0497 2.34 .502
RCT 5 9.12 .0005 ,10
25 .0459 6.09 .511
RCT 6 0.39 .5906 .5868 .0498 1.50 .498
RCT 7 1.81 .2075 .2015 .0471 2.87 .508
RCT 8 2.09 .3731 .3825 .0471 4.48 .457
RCT 9 0.83 .3702 .3730 .0483 1.87 .500
RCT10 1.93 ,10
25 ,10
25 .0468 0.57 .537
RCT 11
a 1.30 .0009 .0006 .0531 0.82 .541
RCT 12 1.10 .0002 .0004 .0492 0.57 .484
Completers
RCT 1 4.72 2610
25 ,10
25 .0474 1.90 .390
RCT 2 2.71 .0140 .0133 .0513 2.18 .480
RCT 3 0.65 .3767 .3759 .0523 1.34 .424
RCT 4 5.32 ,10
25 ,10
25 .0470 2.37 .451
RCT 5 9.34 .0038 .0011 .0484 6.12 .375
RCT 6 0.44 .6058 .6052 .0505 1.66 .468
RCT 7 2.14 .1880 .1842 .0475 2.74 .389
RCT 8 0.56 .8261 .8531 .0379 5.28 .512
RCT 9 1.58 .4435 .4403 .0512 2.27 .176
RCT10 0.88 .3411 .3497 .0500 0.65 .107
RCT 11 1.39 .0029 .0021 .0537 0.92 .490
RCT 12 1.42 .0030 .0038 .0500 0.66 .279
Abbreviations: ITT-LOCF, intent-to-treat-last observation carried forward; RCT, randomized controlled trial.
aIndicates missing data pattern is the same for ITT-LOCF and LOCF. Each permutation test is based on 10,000 permutations of each dataset.
doi:10.1371/journal.pone.0006624.t003
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models were considered, we also compared the Akaike information
criteria (AIC) and Bayesian information criteria (BIC) for the
mixed models in order to see whether one of the methods led to a
consistently better fit. AIC and BIC measure the goodness of fit of
an estimated model and favor models that best explain the data
using the fewest free parameters. Smaller AIC and BIC values
indicate better fit. This analysis confirmed that treating time as a
continuous variable is the preferred approach when there are
many missing data coupled with many time points. Conversely,
treating time as categorical better fits the data when there are
fewer missing data and fewer time points.
Performance Under the Null. As can be seen in Tables 3–5,
most of the empirical a values are close to .05, which is
theoretically expected and desired. Four cases had values of
empirical a,.05: RCT 8 under completers only, RCT 9 under MI
(monotone), RCT 5 under Mixed I Cont., and RCT 5 under
Mixed I Cat. Only the mixed model approaches led to some
conditions with values of empirical a..05, i.e., excess type-1 error
rates. For certain conditions, both RCT 9 and RCT 10 had higher
than expected empirical values under the null. These datasets
represent two of the datasets with the largest amounts of missing
data. Additionally, RCT 9 had one additional problem because an
unstructured covariance could not be fit. Whenever this was
attempted, the program gave either a covariance matrix that was
not positive definite or an infinite likelihood. For that reason, we
chose to impose an AR(1) covariance structure as has been done in
prior studies. It is possible that the difficulty in specifying the
covariance matrix with many time points and much missing data
may contribute to the increased type I error rate.
These results suggest that, at least when missingness is unrelated
to treatment assignment, all of the approaches we evaluated for
handling missing data are adequate for protecting the desired type
I error rate in the majority of realistic cases. However, mixed
model test statistics are prone to increased type I error rates,
particularly if utilized with large amounts of missing data. This is
not too surprising since mixed model test statistics are based on
asymptotic approximations, and others [13,14] have raised
concerns about inflated type I error rates when using these tests.
Performance Under the Alternative Hypothesis:
Power. Tables 3–5 and Figure 3 summarize the results
regarding statistical power. The completers only method has the
least power and worsens with greater DOR. The LOCF methods
have slightly greater power and less variability across datasets. This
appears to be a function of simplicity and stability of the
imputation process. Tables 4 and 5 suggest that the multiple
imputation and mixed model approaches had comparable power,
except in cases with substantial missing data (RCT 9 & RCT 10)
where the mixed model approaches appear more powerful.
Unfortunately, this apparent power advantage of mixed models
Table 4. Analysis of ITT-LOCF, LOCF, and completers for handling missing data in the 12 raw datasets using Multiple Imputation.
Actual Analysis Null Imposed Treatment Effect
MI (Monotone) Observed Mean Difference Observed p-value Permuted p-value Empirical a Mean Difference Power
RCT 1 4.17 4610
25 ,10
25 0.0482 1.92 0.43
RCT 2 2.63 0.0161 0.0146 0.0483 2.18 0.468
RCT 3 0.92 0.2377 0.1688 0.0455 1.32 0.416
RCT 4 5.16 2610
25 ,10
25 0.0473 2.35 0.456
RCT 5 10.08 0.0006 ,10
25 0.0453 6.02 0.42
RCT 6 0.47 0.582 0.74 0.0461 1.65 0.503
RCT 7 1.66 0.3014 0.2052 0.0469 2.75 0.399
RCT 8 2.34 0.3242 0.3821 0.0445 5.3 0.592
RCT 9 1.11 0.6768 0.8025 0.0354 2.28 0.205
RCT 10 1.43 0.0369 0.0481 0.0562 0.65 0.144
RCT 11 1.5 0.0011 0.0009 0.0503 0.93 0.486
RCT 12 1.13 0.0281 0.0168 0.0508 0.66 0.375
MI (MCMC)
RCT 1 4.18 0.0006 0.0005 0.0506 1.92 0.431
RCT 2 3.06 0.0055 0.004 0.0488 2.18 0.473
RCT 3 0.91 0.1817 0.2277 0.0484 1.32 0.429
RCT 4 5.22 1610
25 ,10
25 0.0479 2.35 0.459
RCT 5 10.14 0.0005 ,10
25 0.0478 6.02 0.428
RCT 6 0.3 0.7139 0.6776 0.0481 1.65 0.512
RCT 7 1.89 0.2236 0.1646 0.0492 2.75 0.402
RCT 8 2.22 0.3571 0.3628 0.044 5.3 0.589
RCT 9 1.96 0.2473 0.6461 0.0432 2.26 0.228
RCT 10 1.62 0.0399 0.0198 0.0568 0.65 0.145
RCT11 1.45 0.004 0.0029 0.0498 0.93 0.492
RCT 12 1.21 0.0035 0.0034 0.0506 0.66 0.376
Abbreviations: RCT, randomized controlled trial; MI, multiple imputation. Each permutation test is based on 10,000 permutations of each dataset.
doi:10.1371/journal.pone.0006624.t004
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not adequately hold the type 1 error rate in those situations.
Discussion
Our quantitative survey of the literature on obesity RCTs shows
that missing data are a very substantial problem. Moreover, the
overwhelming majority of published reports use either completers
only or LOCF techniques that have more stringent assumptions
(i.e., completers only) or no theoretical foundation (i.e., LOCF)
and are known to produce biased estimates in many circumstanc-
es. Reasons for this are likely manifold but may include skepticism
on the part of many non-statistician (and some statistician)
investigators’ that the ‘fancier’ techniques such as mixed models
and MI will produce reliable results with real data. Our results
with the analyses of real data show that these more sophisticated
and theoretically well-founded methods generally do not give
wildly different results than the more primitive techniques.
Moreover, in our plasmodes where the right answers are known
yet the data distributions and amounts of missing data are realistic,
MI and the mixed models performed well, except when there were
very large amounts of missing data. These results should provide
reassurance to applied investigators and journal editors and
reviewers that these more sophisticated and theoretically-founded
methods can be used in real obesity RCTs with reasonable
confidence. That being said, when sample sizes are modest, many
data points are missing, and the ratio of measurement points to
patients is high, permutation tests should be encouraged when
using MI or mixed model approaches to analyze weight loss data.
In interpreting our results, several limiting factors should be
kept in mind. First, we only examined the performance of tests at
alpha (type 1 error rate) levels of 0.05. This is a sensible choice
because it seems to be the most commonly used alpha level in
obesity RCTs. However, it is well known that statistical tests that
depend on asymptotic properties, as do many of those that we
evaluated, may perform well at higher alpha levels and be far less
robust at lower alpha levels. Second, anecdotally, we are informed
by several colleagues that since publication of the editorial by
Simons-Morton [15], there has been a great increase in
investigators’ efforts to secure final weights on patients in obesity
RCTs, even for patients who dropout of treatment. In contrast,
this practice did not appear to be used in any of the trials we
analyzed. Finally, we did not construct plasmode datasets in a
manner that preserved any relationship between missing values
and unobserved variables. This is because the nature of such
relationships is not well-understood. We believe that studying
such relations and incorporating models thereof into future
plasmode or simulation studies of the kind we have conducted
Table 5. Mixed Models via Restricted Maximum Likelihood (RML) Treating Time as Continuous.
Actual Analysis Null Imposed Treatment Effect
Mixed I Observed Estimate Observed p-value Permuted p-value Empirical a Estimate Power
RCT 1 4.02 8610
25 ,10
25 0.0435 2.01 0.47
RCT 2 2.88 0.0056 0.0075 0.0602 1.97 0.455
RCT 3 0.79 0.2796 0.2626 0.0493 1.31 0.42
RCT 4 5 ,10
25 ,10
25 0.0454 2.41 0.488
RCT 5 8.99 0.0009 0.0004 0.0323 6.14 0.442
RCT 6 0.37 0.6285 0.6465 0.0569 1.75 0.605
RCT 7 2.44 0.121 0.1163 0.0468 2.37 0.315
RCT 8 2.3 0.3333 0.3339 0.0424 5.32 0.588
RCT 9 0.42 0.7923 0.8026 0.0561 2.2 0.285
RCT 10 1.61 0.0012 0.0064 0.0947 0.72 0.328
RCT 11 1.51 0.001 0.0006 0.0516 0.92 0.498
RCT 12 1.2 0.0038 0.002 0.0031 0.62 0.3
Mixed II
RCT 1 4.78 ,10
25 ,10
25 0.0487 1.86 0.429
RCT 2 2.44 0.0176 0.0228 0.0604 1.61 0.34
RCT 3 0.85 0.2203 0.24 0.0662 1.34 0.475
RCT 4 4.73 1610
25 ,10
25 0.0602 2.61 0.617
RCT 5 9.28 0.0004 0.0003 0.0584 6.07 0.494
RCT 6 0.14 0.8394 0.8517 0.0676 2.21 0.84
RCT 7 2.37 0.1229 0.1354 0.0601 1.88 0.238
RCT 8 2.29 0.3327 0.3366 0.0462 5.32 0.6
RCT 9 0.45 0.6728 0.7853 0.1824 2.3 0.549
RCT 10 1.26 0.0161 0.0171 0.0567 0.75 0.303
RCT 11 1.47 0.0015 0.0013 0.0526 0.93 0.505
RCT 12 1.16 0.0025 0.0041 0.0542 0.62 0.365
Abbreviations: RCT, randomized controlled trial; I, modeling V (variance matrix of y) as a function of G (variance matrix of random effect) and R (random errors); II,
modeling V=R. Each permutation test is based on 10,000 permutations of each dataset.
doi:10.1371/journal.pone.0006624.t005
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less than .05, RCTs in which investigators secure final weights on
patients in obesity RCTs even for patients who drop out of
treatment, and studies with informative missingness must be made
with caution.
Implications for Study Design
To our knowledge, this is the first study to conduct a
comprehensive analysis of DORs in obesity RCTs as a function
of study duration. Landers effectively modeled subject retention in
12-week weight loss trial using survival analysis. The overall
probability of completing that trial was 60% [16]. In our analysis
of published pharmaceutical RCTs, the mean survival rate across
121 studies was 77.7%. Using study duration alone, we predicted
that a study of 52 weeks would have a mean survival (retention)
rate of 63%. The prediction equation (e
2.0088*weeks) may prove
helpful in determining needed sample size and estimating
statistical power in future obesity RCTs that employ pharmaceu-
tical agents. The extent to which this meta-analysis of DORs from
pharmaceutical studies also applies to non-pharmaceutical weight
loss studies remains open to question. Future research is also
needed to examine the impact of study design and study-level
patient characteristics on the prediction of DORs in obesity
RCTS.
Implications for Interpreting Past and Future Obesity
RCTs
Our synthesis of DORs may also be helpful in interpreting
individual RCTs. While we can always (justifiably) note anything
less than perfect follow-up and complete data collection on all
patients as a limitation in any RCT, knowing how that RCT fares
relative to some norm helps put the magnitude of any
accompanying criticism in perspective.
Implications for Selection of Analytic Methods
It is well-established from theory that neither completers only
analyses nor LOCF are guaranteed to return unbiased or consistent
estimates of population effects even under conditions in which MI
and mixed models will return consistent estimates. Thus, given that
MI and mixed models are available, we could only see these ad hoc
methods as justifiable as primary analytic strategies if empirical
evidence showed MI and mixed models to perform poorly withdata
structures typical of obesity RCTs. We have now provided an
evaluation of the possibility and found that MI and mixed models
generally perform quite well with data structures typical of obesity
RCTs. Therefore,we think that MI or mixed models should now be
de rigueur in obesity RCTs with missing data.
This stands in contrast to the FDA’s draft Guidance for Industry
Developing Products for Weight Management which states ‘‘The analysis
Table 6. Mixed Models via Restricted Maximum Likelihood (RML) Treating Time as Categorical.
Actual Analysis Null Imposed Treatment Effect
Mixed I Observed Estimate Observed p-value Permuted p-value Empirical a Estimate Power
RCT 1 4.18 5610
25 5610
25 0.0424 1.89 0.422
RCT 2 2.87 0.0061 0.0061 0.063 2.17 0.514
RCT 3 0.73 0.2968 0.2883 0.0503 1.32 0.449
RCT 4 5.12 ,10
25 ,10
25 0.0467 2.35 0.458
RCT5 9.81 0.0005 0.0002 0.031 6.14 0.411
RCT 6 0.31 0.6811 0.7004 0.0617 1.65 0.557
RCT 7 2.03 0.2056 0.1926 0.0457 2.76 0.405
RCT 8 2.32 0.3297 0.3312 0.0428 5.32 0.588
RCT 9 0.18 0.9107 0.9129 0.0525 2.31 0.304
RCT 10 1.61 0.0071 0.0249 0.1031 0.63 0.241
RCT 11 1.45 0.0016 0.0012 0.0527 0.93 0.501
RCT 12 1.14 0.0068 0.0039 0.0345 0.66 0.333
Mixed II
RCT 1 4.22 4610
25 5610
25 0.0455 1.89 0.433
RCT 2 2.8 0.0101 0.0061 0.052 2.17 0.486
RCT 3 0.82 0.2374 0.2883 0.0555 1.33 0.466
RCT 4 5.21 ,10
25 ,10
25 0.0506 2.35 0.474
RCT 5 9.86 0.0004 0.0002 0.048 6.14 0.464
RCT 6 0.3 0.6987 0.7004 0.0563 1.65 0.531
RCT 7 2.03 0.1925 0.1926 0.0504 2.76 0.428
RCT 8 2.32 0.3284 0.3312 0.0466 5.32 0.598
RCT 9 1.17 0.2681 0.9129 0.1786 2.32 0.557
RCT 10 1.28 0.042 0.0249 0.0565 0.64 0.183
RCT 11 1.42 0.0021 0.0012 0.0516 0.93 0.505
RCT 12 1.13 0.0034 0.0039 0.051 0.66 0.402
Abbreviations: RCT, randomized controlled trial; I, modeling V (variance matrix of y) as a function of G (variance matrix of random effect) and R (random errors); II,
modeling V=R. Each permutation test is based on 10,000 permutations of each dataset.
doi:10.1371/journal.pone.0006624.t006
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population defined as patients who received at least one dose of
study drug and have at least one post-baseline assessment of body
weight. Sensitivity analyses employing other imputation strategies
should assess the effect of dropouts on the results.’’ (See: http://
www.fda.gov/cder/guidance/7544dft.pdf). We believe that our
results coupled with established theory suggest that MI and mixed
models should be methods of choice and LOCF and completers
analysis used only as secondary or sensitivity analyses. That being
said, our results do suggest caution in using mixed models when
sample size is small, time points are many, and the proportion of
data that are missing is high. In such situations, we recommend
coupling mixed models with permutation testing for robustness.
MI seems to have some robustness advantages over mixed models,
and therefore we would recommend it as a method of choice.
Additionally, MI does have other advantages. First, although not
done for this study, MI can use as much of the data as possible by
including other variables that are not explicitly in the model of
interest. Second, once data have been imputed, the imputed data
can be used to conduct a variety of analyses. Lastly, even if the MI
model is incorrect, inferences made from the model of interest
tend to remain valid [9]. That being said, the amount of data
amassed herein suggesting the superiority of MI over mixed
models in the context of RCTs is modest and further research is
warranted.
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